Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu
作者： Ludger Klimek , Pascal Demoly , David Price
DOI: 10.1586/17512433.2016.1148598
关键词:
摘要: For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also effectiveness real-life. Observational studies valuable data on the use and results associated with interventions prescribed However, real-life supporting available AR treatment options sparse established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy omalizumab. A novel formulation azelastine hydrochloride FP a single spray (MP-AzeFlu) shows great promise, observed exceeding that noted RCTs. This review summarises MP-AzeFlu, which provides rapid sustained symptom control irrespective patient age, phenotype or disease severity. We call high quality research addition RCTs inform future guidelines.
elsevier.com
sci-hub.se 参考文章(54)
Zeev Weiler, Yuri Zeldin, Eli Magen, Liran Tiosano, Mona I. Kidon, Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. Israel Medical Association Journal. ,vol. 10, pp. 869- 872 ,(2008)
P. J. Bousquet, C. Combescure, F. Neukirch, J. M. Klossek, H. Méchin, J.-P. Daures, J. Bousquet, Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. ,vol. 62, pp. 367- 372 ,(2007) , 10.1111/J.1398-9995.2006.01276.X
Hartmut Derendorf, Ullrich Munzel, Ursula Petzold, Joachim Maus, Hermann Mascher, Robert Hermann, Jean Bousquet, Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29‐02, a novel aqueous nasal spray British Journal of Clinical Pharmacology. ,vol. 74, pp. 125- 133 ,(2012) , 10.1111/J.1365-2125.2012.04222.X
Pär Stjärne, Victoria Strand, Kaj Theman, Hans Christian Kuhl, Anders Ehnhage, Real-life effectiveness of a new allergic rhinitis therapy (MP29-02*) in Sweden Clinical and Translational Allergy. ,vol. 5, pp. 37- ,(2015) , 10.1186/2045-7022-5-S4-P37
David Price, Pete Smith, Peter Hellings, Nikos Papadopoulos, Wytske Fokkens, Antonella Muraro, Ruth Murray, Alison Chisholm, Pascal Demoly, Glenis Scadding, Joaquim Mullol, Phil Lieberman, Claus Bachert, Ralph Mösges, Dermot Ryan, Jean Bousquet, Current controversies and challenges in allergic rhinitis management Expert Review of Clinical Immunology. ,vol. 11, pp. 1205- 1217 ,(2015) , 10.1586/1744666X.2015.1081814
P. Demoly, P. J. Bousquet, K. Mesbah, J. Bousquet, P. Devillier, Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clinical & Experimental Allergy. ,vol. 43, pp. 881- 888 ,(2013) , 10.1111/CEA.12121
Peter W. Hellings, Antonella Muraro, Wytske Fokkens, Joaquim Mullol, Claus Bachert, G. Walter Canonica, David Price, Nikos Papadopoulos, Glenis Scadding, Gerd Rasp, Pascal Demoly, Ruth Murray, Jean Bousquet, A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clinical and Translational Allergy. ,vol. 5, pp. 36- 36 ,(2015) , 10.1186/S13601-015-0080-9
Uffe Bodtger, Allan Linneberg, Remission of allergic rhinitis: An 8-year observational study Journal of Allergy and Clinical Immunology. ,vol. 114, pp. 1384- 1388 ,(2004) , 10.1016/J.JACI.2004.08.039
Ralph Mösges, All of ARIA in one puff International Archives of Allergy and Immunology. ,vol. 163, pp. 163- 164 ,(2014) , 10.1159/000357188
John Santilli, Robert Nathan, Jeffrey Glassheim, William Rockwell, Patients receiving immunotherapy report it is effective as assessed by the rhinitis outcomes questionnaire (ROQ) in a private practice setting Annals of Allergy, Asthma & Immunology. ,vol. 86, pp. 219- 221 ,(2001) , 10.1016/S1081-1206(10)62694-4